Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Incidence, Clinical Features and Outcome of Patients with Differentiation Syndrome in Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid (ATRA) Alone Versus ATRA Plus Idarubicin Versus ATRA Plus Arsenic Trioxide.

Sameer A Parikh, MD, Hagop Kantarjian, MD, Farhad Ravandi, M.D., Gautam Borthakur, Stefan Faderl, MD, Amit Verma, Alessandra Ferrajoli, MD., Zeev Estrov, MD, Sherry Pierce, Jorge Cortes, MD

Blood (2009) 114 (22): 1044.

https://doi.org/10.1182/blood.V114.22.1044.1044

Published: 2009

Journal Articles

Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS).

Guillermo Garcia-Manero, MD, Francesco Paolo Tambaro, MD, PhD, B. Nebiyou Bekele, PhD, Elias Jabbour, MD, Farhad Ravandi, M.D., Hui Yang, MD, PhD, Gautam Borthakur, MD, Tapan Kadia, MD, Jorge Cortes, MD, Stefan Faderl, MD, Marina Konopleva, MD, PhD, Sherry Pierce, RN, Jan A. Burger, MD, PhD, Zeev Estrov, MD, Susan O'Brien, M.D., Deborah Thomas, Willie Newsome, RN, Hagop Kantarjian, MD

Blood (2009) 114 (22): 1055.

https://doi.org/10.1182/blood.V114.22.1055.1055

Published: 2009

Journal Articles

An Assessment of the RIFLE Criteria for Acute Kidney Injury (AKI) and Mortality in Patients (Pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS).

Gloria Mattiuzzi, MD, Amit Lahoti, Abdulla Salahudeen, Farhad Ravandi, M.D., Jorge Cortes, MD, Khanh Vu, MD, Hagop Kantarjian, MD

Blood (2009) 114 (22): 1013.

https://doi.org/10.1182/blood.V114.22.1013.1013

Published: 2009

Journal Articles

Low Risk of Infectious Events in Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Treated with Dasatinib.

Ali M Al -Ameri, MD, Hagop Kantarjian, MD, Elizabeth Burton, Susan O'Brien, MD, Farhad Ravandi, M.D., Gautam Borthakur, MD, Brenda Walker, Mary Bath Rios, Jorge Cortes, MD

Blood (2009) 114 (22): 3291.

https://doi.org/10.1182/blood.V114.22.3291.3291

Published: 2009

Journal Articles

Phase I Study of Bendamustine in Refractory Leukemia.

Mary Beth Rios, RN, Elias Jabbour, MD, Farhad Ravandi, M.D., Tapan Kadia, MD, Zeev Estrov, MD, Gautam Borthakur, MD, Elizabeth Burton, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 4156.

https://doi.org/10.1182/blood.V114.22.4156.4156

Published: 2009

Journal Articles

Characteristics and Outcome of Patients with Acute Myeloid Leukemia (AML) Refractory to One Cycle of High Dose Cytarabine-Based Induction Chemotherapy.

Farhad Ravandi, M.D., Jorge Cortes, MD, Stefan Faderl, MD, Susan O'Brien, MD, Guillermo Garcia-Manero, MD, Srdan Verstovsek, MD, PhD, Marcos de Lima, MD, Sherry Pierce, RN, Mark Brandt, Gautam Borthakur, MD, Alessandra Ferrajoli, MD., William G. Wierda, M.D., Ph.D, Charles A Koller, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 1038.

https://doi.org/10.1182/blood.V114.22.1038.1038

Published: 2009

Journal Articles

Long Term Followup and Patterns of Failure in Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Treated On Studies Combining a Hypomethylating Agent and the Histone Deacetylase Inhibitor (HDACi) Valproic Acid.

Tapan Kadia, MD, Zeev Estrov, MD, Farhad Ravandi, M.D., Charles Asa Koller, MD, Gautam Borthakur, MD, Elias Jabbour, MD, Stefan Faderl, MD, Sherry Pierce, RN, Jorge Cortes, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2009) 114 (22): 2074.

https://doi.org/10.1182/blood.V114.22.2074.2074

Published: 2009

Journal Articles

Outcomes of Salvage Treatment in Patients with Acute Myeloid Leukemia (AML) with FLT3 Mutations.

Yiming Chen, MD., PhD., Jorge Cortes, MD, E. Lin, Farhad Ravandi, M.D., Stefan Faderl, MD, Tapan Kadia, MD, Hagop M. Kantarjian, MD, Gautam Borthakur, MD

Blood (2009) 114 (22): 2078.

https://doi.org/10.1182/blood.V114.22.2078.2078

Published: 2009

Journal Articles

Pediatric-Based Therapy for Young Adults with Newly Diagnosed Lymphoblastic Leukemia.

Michael Rytting, M.D., Deborah A. Thomas, MD, Anna R Franklin, Elias Jabbour, William Wierda, MD, PhD, Stefan Faderl, MD, Robert Wells, MD, Tapan Kadia, MD, Farhad Ravandi, M.D., Alessandra Ferrajoli, MD., Jorge Cortes, MD, Susan O'Brien, Hagop Kantarjian, MD

Blood (2009) 114 (22): 2037.

https://doi.org/10.1182/blood.V114.22.2037.2037

Published: 2009

Journal Articles

Young Adults with Acute Lymphoblastic Leukemia (ALL) Treated with Adapted Augmented Berlin-Frankfurt-Munster (ABFM) Therapy

Michael Rytting, M.D., Deborah Thomas, M.D., Anna Franklin, M.D., William Wierda, M.D., Stefan Faderl, M.D., Farhad Ravandi, M.D., Brenda Muriera, RN, Hagop M. Kantarjian, MD, Susan O’Brien, M.D.

Blood (2008) 112 (11): 3957.

https://doi.org/10.1182/blood.V112.11.3957.3957

Published: 2008

Journal Articles

SNS-595 Demonstrates Clinical Responses in a Phase 1 Study in Acute Leukemia.

Jeffrey Lancet, MD, Hagop Kantarjian, M.D., Farhad Ravandi, M.D., Sem Bastien, R.N., Katrina Alino, R.N., Glenn Michelson, M.D., Judith Karp, M.D.

Blood (2007) 110 (11): 442.

https://doi.org/10.1182/blood.V110.11.442.442

Published: 2007

Journal Articles

Bleeding Diathesis in Patients (pts) with Chronic Myelogenous Leukemia Receiving Dasatinib Therapy.

Alfonso Quintás-Cardama, MD, Hagop Kantarjian, M.D., Farhad Ravandi, M.D., Jan Burger, M.D., Gautam Borthakur, M.D., Jorge Cortes, M.D.

Blood (2007) 110 (11): 2958.

https://doi.org/10.1182/blood.V110.11.2958.2958

Published: 2007

Journal Articles

Adaptation of Augmented Berlin-Frankfurt-Munster (ABFM) Therapy in Adolescents and Young Adults with Acute Lymphoblastic Leukemia (ALL).

Michael Rytting, MD, Deborah Thomas, M.D., Hagop Kantarjian, M.D., Jorge Cortes, M.D., Gautam Borthakur, M.D., William Wierda, M.D., Cesar Nunez, M.D., Steven Kornblau, M.D., Farhad Ravandi, M.D., Robert Wells, M.D., Muriera Brenda, R.N., Franklin Anna, M.D., Susan O’Brien, M.D.

Blood (2007) 110 (11): 4342.

https://doi.org/10.1182/blood.V110.11.4342.4342

Published: 2007

Journal Articles

Phase II Study of Lenalidomide and Prednisone for Patients with Myelofibrosis.

Alfonso Quintás-Cardama, MD, Ayalew Tefferi, M.D., Deborah Thomas, M.D., Jorge Cortes, M.D., Farhad Ravandi, M.D., Stefan Faderl, M.D., Guillermo Garcia-Manero, M.D., Gautam Borthakur, M.D., Neda Bell, M.D., Catriona Byrne, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D., Ph.D

Blood (2007) 110 (11): 3545.

https://doi.org/10.1182/blood.V110.11.3545.3545

Published: 2007

Journal Articles

Development of Forodesine Hydrochloride (FH), an Inhibitor of Purine Nucleoside Phosphorylase, for Patients with Chronic Lymphocytic Leukemia (CLL).

Kumudha Balakrishnan, PhD, Farhad Ravandi, M.D, Michael J. Keating, M.D, Varsha Gandhi, Ph.D

Blood (2005) 106 (11): 2119.

https://doi.org/10.1182/blood.V106.11.2119.2119

Published: 2005

NARROW

Incidence, Clinical Features and Outcome of Patients with Differentiation Syndrome in Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid (ATRA) Alone Versus ATRA Plus Idarubicin Versus ATRA Plus Arsenic Trioxide.

Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS).

An Assessment of the RIFLE Criteria for Acute Kidney Injury (AKI) and Mortality in Patients (Pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS).

Low Risk of Infectious Events in Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Treated with Dasatinib.

Phase I Study of Bendamustine in Refractory Leukemia.

Characteristics and Outcome of Patients with Acute Myeloid Leukemia (AML) Refractory to One Cycle of High Dose Cytarabine-Based Induction Chemotherapy.

Long Term Followup and Patterns of Failure in Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Treated On Studies Combining a Hypomethylating Agent and the Histone Deacetylase Inhibitor (HDACi) Valproic Acid.

Outcomes of Salvage Treatment in Patients with Acute Myeloid Leukemia (AML) with FLT3 Mutations.

Pediatric-Based Therapy for Young Adults with Newly Diagnosed Lymphoblastic Leukemia.

Young Adults with Acute Lymphoblastic Leukemia (ALL) Treated with Adapted Augmented Berlin-Frankfurt-Munster (ABFM) Therapy

SNS-595 Demonstrates Clinical Responses in a Phase 1 Study in Acute Leukemia.

Bleeding Diathesis in Patients (pts) with Chronic Myelogenous Leukemia Receiving Dasatinib Therapy.

Adaptation of Augmented Berlin-Frankfurt-Munster (ABFM) Therapy in Adolescents and Young Adults with Acute Lymphoblastic Leukemia (ALL).

Phase II Study of Lenalidomide and Prednisone for Patients with Myelofibrosis.

Development of Forodesine Hydrochloride (FH), an Inhibitor of Purine Nucleoside Phosphorylase, for Patients with Chronic Lymphocytic Leukemia (CLL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only